QLGN Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own QLGN shares is 19, representing 1.77% of the company's common stock.

, in the last quarter, reduced its stake in QLGN by -100% restricting it's holding to 0 shares of worth nearly -. SUSQUEHANNA INTERNATIONAL GROUP, LLP also lessened -62.46% of the QLGN shares from its portfolio, reducing its holding to 22.9 thousand shares of worth $6.00K. CITADEL ADVISORS LLC also shunned QLGN shares holding by -71.93% last quarter which brought its holding to 12.1 thousand shares worth $3.00K.

As per its latest 13F filing, UBS GROUP AG increased its stake in QLGN by 866.25% in the last quarter. The institutional holder raised its holding to 56.78 thousand shares having worth more than $16.00K. BANK OF AMERICA CORP /DE/ also added 36.91% more shares of QLGN to its portfolio, raising its holding to 47.96 thousand shares of worth $13.00K. RENAISSANCE TECHNOLOGIES LLC also increased its QLGN shares holding by 100% which brought its holding to 14.5 thousand shares worth $4.00K.

The insider with the most stakes in QLGN is Javelin Venture Partners, L.P. , 10 percent owner at the company. Additionally, QLGN stock is highly held by director Doyle Noah and Chairman and CEO Poirier Michael S. among others.

Company executives, directors, and other insiders own 3.77% percent of Qualigen Therapeutics, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which QLGN insiders have sold stock, totaling 0 shares. Insiders that have sold shares include DOYLE NOAH, RITTER IRA E., and RITTER ANDREW J.

There have been 0 transaction(s) during the past 6-months in which Qualigen Therapeutics, Inc. insiders have bought stock, totalling 0 shares

Around 0 Qualigen Therapeutics, Inc. shares are held by insiders, which represents about 3.77% of QLGN stock.

QLGN 10 percent owner, Javelin Venture Partners, L.P. holds the largest portfolio of the company's shares. QLGN shares owned by Javelin total nearly 5 million.

is the largest institutional owner in QLGN which holds 0 shares worth - or 0% of the total QLGN shares outstanding followed by HIGHMARK WEALTH MANAGEMENT LLC with ownership of 80.09 thousand shares representing 0.2% of the QLGN ownership. UBS GROUP AG is the third largest stakeholder with 56.78 thousand shares or 0.14% of the ownership worth more than $16.00K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the QLGN is concerned, it is a stock which is not optionable.

Number of QLGN shares short is 15.59K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 736.43K shares of QLGN are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, QLGN has 242.92K shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for QLGN is 0.11.